Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?

Detalles Bibliográficos
Autor principal: Brass, Eric P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687289/
https://www.ncbi.nlm.nih.gov/pubmed/23695815
http://dx.doi.org/10.2337/dc13-0891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687289/
https://www.ncbi.nlm.nih.gov/pubmed/23695815
http://dx.doi.org/10.2337/dc13-0891

Ejemplares similares